Twitty Christopher 4

What Happened

• Christopher Twitty, Chief Scientific Officer of Skye Bioscience (SKYE), was granted a derivative award covering 150,000 shares on Feb 6, 2026. The Form 4 reports an acquisition price of $0.00 for the award (i.e., a stock-option/award grant) with no immediate cash value reported.

Key Details

• Transaction date: 2026-02-06; Form 4 filed: 2026-02-09 (appears timely).
• Reported acquisition: 150,000 derivative shares at $0.00 (reported as an award/grant).
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Footnote: The award vests in equal monthly installments over a four-year period beginning January 19, 2026.
• Filing timeliness: filed Feb 9, 2026 — within the typical two-business-day Section 16 reporting window for a Feb 6 transaction.

Context

• This was an award/grant (not an open-market purchase or sale). For retail investors, grants signal compensation or retention incentives rather than direct insider buying/selling; they do not necessarily indicate immediate bullish or bearish sentiment.
• The derivative award vests over time, so it will become valuable to the insider only as portions vest and (if applicable) are exercisable according to plan terms.